Tag: Boston Scientific

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
SpaceOAR

Boston Scientific announces agreement to acquire Augmenix

  Boston Scientific has announced that it has entered into a definitive agreement to acquire Augmenix, a privately-held company which has developed and commercialised the...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Explore how to enhance your ability to access challenging treatment sites

This content is for distribution within USA only. The Direxion™ Microcatheter, with its unique shaft design, offers you unrivaled torqueability for improved maneuverability. Further enhancing...

Our guidewire design revolutionizes the ability to access even the most...

This content is for distribution within USA only. As you pursue new and innovative procedures within more complex anatomy, you need precision and control like...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

Eluvia paclitaxel-eluting stent shows long-term freedom from revascularisation at three years

Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological...